• By Douglas Johnson, MD, MSCI, Assistant Professor of Medicine & Clinical Director, Melanoma, Vanderbilt-Ingram Cancer Center  |  May 31, 2017

    Profiling Melanoma to Predict Immune Therapy Success

    May is Melanoma awareness month, and our series on melanoma continues with a discussion with Dr. Douglas B. Johnson of the Vanderbilt-Ingram Cancer Center. Dr. Johnson leads Vanderbilt’s melanoma clinical and research program, overseeing clinical trials, patient care and translational research. His research interests focus on developing new immune and…more.

Chat Avatar